Literature DB >> 8293401

Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast.

G F Schwartz1, C A Birchansky, L T Komarnicky, C M Mansfield, R I Cantor, W A Biermann, F M Fellin, J McFarlane.   

Abstract

BACKGROUND: Few women with locally advanced breast cancer remain disease-free, even for 2 years. Response to induction chemotherapy may be associated with longer disease-free and overall survival rates. The role of breast conservation in selected patients with response to induction chemotherapy was evaluated.
METHODS: Since 1979, patients with Stages IIB and III breast cancer have undergone induction chemotherapy; patients with response continued chemotherapy until a plateau of regression was achieved. Before 1983, all patients having a response to chemotherapy underwent mastectomy; since 1983, selected patients have undergone breast conservation. Outcomes were tallied comparing these two groups of patients.
RESULTS: The study group included 189 women, who were followed up for 12-159 months (median, 46 months) after diagnosis. Of the patients, 85% had a response to induction chemotherapy. Patients with no response were excluded from additional consideration in this study. One hundred three (64%) women underwent mastectomy; 55 (36%) were treated with breast conservation. The disease-free 5-year survival rate was 61% for all patients with a response to chemotherapy; 56% for those having mastectomy and 77% for those having breast conservation. The overall 5-year survival rate was 69% for all patients with a response to chemotherapy, 67% for those undergoing mastectomy and 80% for those having breast conservation.
CONCLUSIONS: Induction chemotherapy achieves significant tumor regression in most women with locally advanced breast cancer, permitting subsequent breast conservation or mastectomy with a greater expectation of long-term success. Breast conservation is used more frequently with the same expectation of success as mastectomy, presuming careful selection based on response to chemotherapy.

Entities:  

Mesh:

Year:  1994        PMID: 8293401     DOI: 10.1002/1097-0142(19940115)73:2<362::aid-cncr2820730221>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  42 in total

1.  Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.

Authors:  Sylvia Adams; A Bapsi Chakravarthy; Martin Donach; Darcy Spicer; Stella Lymberis; Baljit Singh; Joshua A Bauer; Tsivia Hochman; Judith D Goldberg; Franco Muggia; Robert J Schneider; Jennifer A Pietenpol; Silvia C Formenti
Journal:  Breast Cancer Res Treat       Date:  2010-09-29       Impact factor: 4.872

2.  Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.

Authors:  Mónica Fernández-Sánchez; Armando Gamboa-Dominguez; Norma Uribe; Ana Cristina García-Ulloa; Diana Flores-Estrada; Myrna Candelaria; Oscar Arrieta
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Aziz Cengiz; Hüseyin Altınyollar
Journal:  World J Surg       Date:  2007-09       Impact factor: 3.352

4.  Oncoplastic surgery combining partial mastectomy with breast reconstruction using a free nipple-areola graft for ductal carcinoma in situ in a ptotic breast: report of a case.

Authors:  Yuko Kijima; Heiji Yoshinaka; Munetsugu Hirata; Tadao Mizoguchi; Sumiya Ishigami; Hideo Arima; Akihiro Nakajo; Shinichi Ueno; Shoji Natsugoe
Journal:  Surg Today       Date:  2011-03-02       Impact factor: 2.549

5.  Lymph node status in inflammatory breast cancer.

Authors:  Julie S Wecsler; Welela Tereffe; Rose C Pedersen; Michelle R Sieffert; Wendy J Mack; Haiyan Cui; Christy A Russell; Ryan R Woods; Rebecca K Viscusi; Stephen F Sener; Julie E Lang
Journal:  Breast Cancer Res Treat       Date:  2015-04-07       Impact factor: 4.872

6.  Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.

Authors:  Konstantinos Papadimitriou; Konstantinos Papademetriou; Alexandros Ardavanis; Panteleimon Kountourakis
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

7.  Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy.

Authors:  Catherine L Akay; Funda Meric-Bernstam; Kelly K Hunt; Elizabeth G Grubbs; Isabelle Bedrosian; Susan L Tucker; Henry M Kuerer; Karen E Hoffman; Gildy V Babiera; Eric A Strom; Thomas A Buchholz; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2011-08-23       Impact factor: 5.344

8.  Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy.

Authors:  Regine Choe; Turgut Durduran
Journal:  IEEE J Sel Top Quantum Electron       Date:  2011-12-02       Impact factor: 4.544

Review 9.  Management of patients with locally advanced breast cancer.

Authors:  Lisa A Newman
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

10.  Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer.

Authors:  Samuel W Beenken; Marshall M Urist; Yuting Zhang; Renee Desmond; Helen Krontiras; Heriberto Medina; Kirby I Bland
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.